Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shares dropped 5.6% on Thursday . The company traded as low as $26.58 and last traded at $26.63. Approximately 147,687 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 261,680 shares. The stock had previously closed at $28.21.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.
Get Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Trading Down 4.4 %
The stock has a market cap of $1.27 billion, a P/E ratio of -13.97 and a beta of 1.10. The firm has a 50-day simple moving average of $23.34 and a two-hundred day simple moving average of $22.22.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.
Insiders Place Their Bets
In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $26.70, for a total transaction of $320,400.00. Following the transaction, the insider now owns 1,093,035 shares in the company, valued at $29,184,034.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Samuel Kintz sold 2,270 shares of the firm's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total value of $62,561.20. Following the transaction, the chief executive officer now owns 1,061,255 shares in the company, valued at approximately $29,248,187.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the firm's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $26.70, for a total value of $320,400.00. Following the completion of the transaction, the insider now owns 1,093,035 shares in the company, valued at $29,184,034.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 231,862 shares of company stock worth $6,086,188 in the last 90 days. Company insiders own 29.20% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Quest Partners LLC boosted its stake in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after buying an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after buying an additional 3,189 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Enliven Therapeutics in the first quarter valued at about $167,000. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the third quarter valued at about $256,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics in the second quarter valued at about $322,000. Institutional investors own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
